Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Paola Guglielmelli; Arianna Ghirardi; Alessandra Carobbio; Arianna Masciulli; Chiara Maccari; Barbara Mora; Elisa Rumi; Ana Triguero; Maria Chiara Finazzi; Helna Pettersson; Chiara Paoli; Francesco Mannelli; Daniele Vanni; Alessandro Rambaldi; Francesco Passamonti; Alberto Álvarez‐Larrán; Björn Andréasson; Alessandro M. Vannucchi; Tiziano Barbui

doi:10.1182/bloodadvances.2021006006

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Survival in patients with myelofibrosis (MF), median overall survival (OS) of 6 to 7 years, is shorter than that of the general population.1 MF is also associated with profound negative effects on quality of life.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Guglielmelli et al. (2021) studied this question.

synapsesocial.com/papers/6a104621e1a472cb5efc9933 https://doi.org/10.1182/bloodadvances.2021006006

View Full Paper

Ask AI

Bookmark

Share

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Ask about this paper

Abstract

Discussion

Cite This Study

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading